Claritev Corporation

NYSE:CTEV

Medical - Healthcare Information Services

Healthcare
$22.30 +1.41%

+$0.42 today

Market cap
$380.77M
Beta
0.77
P/E (TTM)
-1.8
EPS (TTM)
-$17.16
52W Low $11.50High $74.07

Volume 0.31M

Average 0.14M

CTEV Income Before Tax

Profit after all operating and non-operating items but before income tax.

Claritev CorporationNYSE: CTEV

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$92.72M, compared with -$89.87M a year earlier. Trailing-twelve-month income before tax was -$328.72M.

Context

  • Income before tax amounted to 38.6% of revenue in FY2025, down 151.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$92.72M or moves back toward the trailing-twelve-month quarterly average of -$82.18M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$92.72M+13.3% QoQ
Last fiscal yearDec 2025
-$373.08M+78.9% YoY
LTMMar 2026
-$328.72M+74.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.2%——
1 year+78.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(373.08M) USD
Year-over-year change
+78.9%

Income Before Tax vs competitors

How CTEV compares with its peers on the latest reported figures

  • CTEV's LTM Mar 2026 income before tax of -$328.72M is the 9th highest of the 11 companies compared; the peer median is -$30.92M.
  • Its year-over-year change of +74.7% is the highest of 11, against a peer median of -45.6%.
  • Income before tax amounts to 33.6% of revenue for CTEV, versus a peer median of 27.3%.
CTEV Competitors Peer median
Income Before Tax for CTEV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INMDInMode Ltd.LTM Mar 2026$102.21M -26.9%-18.2%27.3%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$45.51M -4.9%—5.8%
IRMDIRadimed CorporationLTM Mar 2026$30.18M +20.8%+20.6%35.0%
LFMDLifeMD, Inc.LTM Mar 2026-$14.9M -64.3%—6.8%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.91M +73.9%—1570.9%
AXGNAxoGen, Inc.LTM Sep 2026-$31.92M -1422.3%—12.0%
OPKOPKO Health, Inc.LTM Mar 2026-$228.97M -40353.7%—39.4%
SANASana Biotechnology, Inc.LTM Mar 2026-$241.99M -16.0%——
CTEVClaritev CorporationLTM Mar 2026-$328.72M +74.7%—33.6%
EVHEvolent Health, Inc.LTM Mar 2026-$497.21M -354.2%—26.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-$535.88M -1145.0%—32.6%
Peer median (excluding CTEV) -$30.92M-45.6%+1.2%27.3%

Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12B1.08B961.52M930.62M965.41M
Cost of Revenue175.29M204.1M235.47M239.4M698.84M
Gross Profit942.31M875.62M726.06M691.22M266.58M
Gross Margin84.3%81.1%75.5%74.3%27.6%
Research & Development00000
Selling, General & Admin151.1M132.14M135.99M160.22M221.52M
Operating Expenses556.19M1.24B564.07M2.08B221.52M
Depreciation & Amortization412.06M415.66M425.79M436.44M448.45M
EBITDA814.99M158.32M651.93M(1.01B)475.44M
EBITDA Margin72.9%14.7%67.8%-108.3%49.2%
Operating Income386.12M(362.73M)161.98M(1.39B)45.06M
Operating Margin34.5%-33.6%16.8%-149.4%4.7%
Interest Income30K3.5M8.23M3.13M1.56M
Interest Expense267.48M303.4M333.21M326.37M400.07M
Other Income / Expenses(250.67M)(198.01M)(269.04M)(380.78M)(418.14M)
Income Before Tax135.45M(560.74M)(107.06M)(1.77B)(373.08M)
Pre-Tax Margin12.1%-51.9%-11.1%-190.3%-38.6%
Income Tax Expense33.37M12.17M(15.36M)(124.88M)(88.8M)
Net Income102.08M(572.91M)(91.7M)(1.65B)(284.28M)
Net Margin9.1%-53.1%-9.5%-176.9%-29.4%
EPS (Basic)6.40(35.87)(5.69)(101.92)(17.30)
EPS (Diluted)6.40(35.87)(5.69)(101.92)(17.30)
Weighted Avg Shares16.28M15.97M16.13M16.15M16.43M
Weighted Avg Shares (Diluted)16.29M15.97M16.13M16.15M16.43M

Claritev Corporation

NYSE:CTEV

Intrinsic Alpha fair value

Locked

Current Price

$22.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.